CASE Comprehensive Cancer Center, Cleveland, Ohio;
University of Pittsburgh Medical Center, Pittsburgh, Pa
Background: Epidermal growth factor receptor (EGFR) is highly expressed in squamous cell cancer of the head and neck (SCCHN), representing a promising therapeutic target. Erlotinib (E) is an EGFR tyrosine kinase inhibitor that may potentiate the efficacy of concurrent radiation (RT) and docetaxel (D). We sought to establish the maximum tolerated dose, toxic effects, and preliminary efficacy of the combination of RT, D and E in patients with SCCHN.
Savvides PS, Agarwala SS, Greskovich J, Argiris A, Bokar J, Pagedar N, Hoppel C, Stepnick DW, Remick S, Lavertu P. P001 Phase 1 Study of Erlotinib, Docetaxel, and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck. Arch Otolaryngol Head Neck Surg. 2006;132(8):865. doi:10.1001/archotol.132.8.865-a